Pergolide is a dopamine receptor agonist, primarily used in the treatment of Parkinson’s disease and hyperprolactinemia. It acts on dopamine D1 and D2 receptors to help restore dopamine activity in the brain, which is crucial for motor control. Pergolide was also used in veterinary medicine, particularly for the treatment of equine Cushing’s disease (pituitary pars intermedia dysfunction or PPID).
Although pergolide was effective, its use in human medicine has been withdrawn in several countries, including the United States, due to the risk of valvular heart disease. It remains approved in veterinary settings, especially for long-term endocrine management in horses.
Parent: Pergolide
Parent: Pergolide
Parent: Pergolide
Parent: Pergolide
Impurities in pergolide may arise from synthesis steps, degradation, or formulation issues, and are subject to regulatory controls to ensure safety and efficacy, especially in veterinary applications.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
In humans (when it was in use):
In veterinary use (e.g., in horses):
